• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿巴西普（CTLA4-Ig）不断演变的临床概况：一种用于治疗类风湿关节炎的新型共刺激调节剂

The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.

作者信息

Ruderman Eric M, Pope Richard M

机构信息

Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

出版信息

Arthritis Res Ther. 2005;7 Suppl 2(Suppl 2):S21-5. doi: 10.1186/ar1688. Epub 2005 Mar 16.

DOI:10.1186/ar1688
PMID:15833145
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2833980/
Abstract

Abatacept (CTLA4-Ig) is a novel fusion protein designed to modulate the T cell co-stimulatory signal mediated through the CD28-CD80/86 pathway. Clinical trials have provided preliminary evidence of the efficacy of this compound in the treatment of rheumatoid arthritis. This review describes the molecular and biologic bases for the use of abatacept in rheumatoid arthritis and summarizes the current clinical data on its safety and effectiveness in this disease.

摘要

阿巴西普（CTLA4-Ig）是一种新型融合蛋白，旨在调节通过CD28-CD80/86途径介导的T细胞共刺激信号。临床试验已提供了该化合物治疗类风湿关节炎有效性的初步证据。本综述描述了阿巴西普用于类风湿关节炎治疗的分子和生物学基础，并总结了目前关于其在该疾病中安全性和有效性的临床数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4a/2833980/f0d1437acb33/ar1688-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4a/2833980/f7f7629c7fac/ar1688-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4a/2833980/f0d1437acb33/ar1688-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4a/2833980/f7f7629c7fac/ar1688-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4a/2833980/f0d1437acb33/ar1688-2.jpg

相似文献

1
The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.阿巴西普（CTLA4-Ig）不断演变的临床概况：一种用于治疗类风湿关节炎的新型共刺激调节剂
Arthritis Res Ther. 2005;7 Suppl 2(Suppl 2):S21-5. doi: 10.1186/ar1688. Epub 2005 Mar 16.
2
Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.阿巴西普，一种新型的CD80/86-CD28 T细胞共刺激调节剂，用于治疗类风湿性关节炎。
Basic Clin Pharmacol Toxicol. 2009 Apr;104(4):276-84. doi: 10.1111/j.1742-7843.2009.00375.x. Epub 2009 Feb 18.
3
Abatacept mechanism of action: concordance with its clinical profile.阿巴西普的作用机制：与其临床特征相符。
Reumatol Clin. 2012 Mar-Apr;8(2):78-83. doi: 10.1016/j.reuma.2011.08.002. Epub 2011 Nov 21.
4
Technology evaluation: abatacept, Bristol-Myers Squibb.技术评估：阿巴西普，百时美施贵宝公司
Curr Opin Mol Ther. 2004 Jun;6(3):318-30.
5
Role of abatacept in the management of rheumatoid arthritis.阿巴西普在类风湿关节炎治疗中的作用。
Clin Ther. 2006 Nov;28(11):1764-78. doi: 10.1016/j.clinthera.2006.11.020.
6
T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.对葡萄球菌肠毒素B耐受的自身免疫性MRL-lpr/lpr小鼠的T细胞需要通过B7-CD28/CTLA-4途径进行共刺激才能激活，并且在缺乏这种共刺激信号的情况下，通过刺激T细胞受体可在体内再次失能。
Eur J Immunol. 1994 May;24(5):1019-25. doi: 10.1002/eji.1830240502.
7
Drug Insight: abatacept for the treatment of rheumatoid arthritis.药物洞察：阿巴西普用于治疗类风湿关节炎。
Nat Clin Pract Rheumatol. 2006 Dec;2(12):654-60. doi: 10.1038/ncprheum0345.
8
Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig.BB大鼠的胶原诱导性关节炎。用CTLA-4-Ig治疗预防疾病。
J Clin Invest. 1995 Aug;96(2):987-93. doi: 10.1172/JCI118146.
9
Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.阿巴西普：皮肤科医生对一种用于难治性类风湿关节炎的新型生物制剂的综述。
J Dermatolog Treat. 2006;17(4):229-34. doi: 10.1080/09546630600788885.
10
Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept.类风湿关节炎中的共刺激调节：阿巴西普（CTLA4-Ig）的作用
Autoimmun Rev. 2008 Oct;8(1):76-82. doi: 10.1016/j.autrev.2008.07.035. Epub 2008 Aug 15.

引用本文的文献

1
Immunosuppression Management in Heart Transplantation.心脏移植中的免疫抑制管理
Methodist Debakey Cardiovasc J. 2025 May 15;21(3):40-50. doi: 10.14797/mdcvj.1596. eCollection 2025.
2
The Role of the CD28 Family Receptors in T-Cell Immunomodulation.CD28家族受体在T细胞免疫调节中的作用
Int J Mol Sci. 2024 Jan 20;25(2):1274. doi: 10.3390/ijms25021274.
3
CD4CD25 T regulatory cells in renal transplantation.肾移植中的 CD4CD25T 调节性细胞。

本文引用的文献

1
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.通过融合蛋白CTLA4Ig选择性抑制T细胞活化来治疗类风湿性关节炎。
N Engl J Med. 2003 Nov 13;349(20):1907-15. doi: 10.1056/NEJMoa035075.
2
Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells.前沿：CD28调控CD4+CD25+调节性T细胞的外周稳态。
J Immunol. 2003 Oct 1;171(7):3348-52. doi: 10.4049/jimmunol.171.7.3348.
3
The expansion of CD4+CD28- T cells in patients with rheumatoid arthritis.类风湿关节炎患者中CD4+CD28- T细胞的扩增。
Front Immunol. 2022 Nov 8;13:1017683. doi: 10.3389/fimmu.2022.1017683. eCollection 2022.
4
A Novel Therapeutic Effect of a New Variant of CTLA4-Ig with Four Antennas That Are Terminally Capped with Sialic Acid in the CTLA4 Region.CTLA4区域中具有四个末端被唾液酸封端天线的CTLA4-Ig新变体的一种新型治疗效果。
Biomol Ther (Seoul). 2022 Nov 1;30(6):529-539. doi: 10.4062/biomolther.2022.071. Epub 2022 Sep 29.
5
Analysis of the Immunogenicity from Abatacept-Treated Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Findings From Two Phase III Clinical Trials.阿巴西普治疗多关节型幼年特发性关节炎儿科患者的免疫原性分析：两项III期临床试验的结果
ACR Open Rheumatol. 2022 Feb;4(2):177-186. doi: 10.1002/acr2.11375. Epub 2021 Nov 18.
6
Current and future therapies for primary Sjögren syndrome.原发性干燥综合征的当前和未来治疗方法。
Nat Rev Rheumatol. 2021 Aug;17(8):475-486. doi: 10.1038/s41584-021-00634-x. Epub 2021 Jun 29.
7
Biologic therapy in Sjögren's syndrome.干燥综合征的生物治疗。
Clin Rheumatol. 2021 Jun;40(6):2143-2154. doi: 10.1007/s10067-020-05429-1. Epub 2020 Oct 27.
8
The pathogenesis and treatment in antineutrophil cytoplasmic antibody associated vasculitis.抗中性粒细胞胞浆抗体相关性血管炎的发病机制与治疗
Am J Transl Res. 2020 Aug 15;12(8):4094-4107. eCollection 2020.
9
Human immunology and immunotherapy: main achievements and challenges.人类免疫学和免疫疗法：主要成就和挑战。
Cell Mol Immunol. 2021 Apr;18(4):805-828. doi: 10.1038/s41423-020-00530-6. Epub 2020 Sep 2.
10
Vitamin D, Calcium, Parathyroid Hormone, and Sex Steroids in Bone Health and Effects of Aging.维生素D、钙、甲状旁腺激素和性类固醇在骨骼健康及衰老影响中的作用
J Osteoporos. 2020 Jun 17;2020:9324505. doi: 10.1155/2020/9324505. eCollection 2020.
Arthritis Res Ther. 2003;5(4):R210-3. doi: 10.1186/ar766. Epub 2003 May 14.
4
Abandoned therapies and unpublished trials in rheumatoid arthritis.类风湿关节炎中被废弃的疗法及未发表的试验
Curr Opin Rheumatol. 2003 May;15(3):253-8. doi: 10.1097/00002281-200305000-00012.
5
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.类风湿关节炎患者共刺激阻断：一项先导性、剂量探索性、双盲、安慰剂对照临床试验，在首次输注85天后评估CTLA-4Ig和LEA29Y。
Arthritis Rheum. 2002 Jun;46(6):1470-9. doi: 10.1002/art.10294.
6
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.CD28/B7：CTLA-4共刺激通路在自身免疫和移植中的复杂性
Annu Rev Immunol. 2001;19:225-52. doi: 10.1146/annurev.immunol.19.1.225.
7
Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide.前沿：CTLA4Ig与环磷酰胺逆转小鼠狼疮性肾炎
J Immunol. 2001 Mar 1;166(5):2913-6. doi: 10.4049/jimmunol.166.5.2913.
8
A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade.B7/CD28共刺激在实验性自身免疫性脑脊髓炎中的关键作用：一项使用共刺激分子缺陷小鼠和单克隆抗体阻断的比较研究
J Immunol. 2000 Jan 1;164(1):136-43. doi: 10.4049/jimmunol.164.1.136.
9
CD28-deficient mice are highly resistant to collagen-induced arthritis.CD28基因缺陷型小鼠对胶原诱导性关节炎具有高度抗性。
J Immunol. 1999 Jan 1;162(1):203-8.
10
CTLA-4 regulates tolerance induction and T cell differentiation in vivo.细胞毒性T淋巴细胞相关抗原4（CTLA-4）在体内调节耐受性诱导和T细胞分化。
J Immunol. 1998 Apr 15;160(8):3855-60.